EANS-News: AGENNIX AG / Agennix AG to Present at Three Conferences in February

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and
Houston, TX, January 30, 2012 - Agennix AG (Frankfurt Stock Exchange:
AGX) today announced that the Company will be presenting at three
conferences in February.

Close Brothers Seydler Bank AG Small and Mid Cap Conference,
Frankfurt Agennix will give a presentation at the Close Brothers
Seydler Bank AG Small and Mid Cap Conference. The presentation will
be on Wednesday, February 1, 2012, at 12:30 CET at the IHK Frankfurt
(Boerse), Frankfurt am Main, Germany.

German Science Day, Berlin The Company will give a presentation and
participate in a panel discussion on cancer immunotherapies and
oligonucleotides as part of German Science Day at the University
hospital Charité in Berlin, Germany. The presentation is scheduled
for Thursday, February 2, 2012, at 15:35 CET. A live webcast of the
presentation in German will be available through the Agennix Web site
at www.agennix.com. A replay in German and English will be available
on the Web site following the live event.

The First German Science Day - Fight Cancer, an initiative of the
German biotechnology industry, will take place on the occasion of
World Cancer Day. The event will highlight the major research and
development contributions of German biotechnology companies working
in the field of cancer to the press, investors and analysts. More
information on German Science Day (German language only) can be found
at www.german-science-day.com.

BIO CEO & Investor Conference, New York City Agennix will also give a
presentation at the 14th Annual BIO CEO & Investor Conference in New
York, NY, USA. The presentation is scheduled for Tuesday, February
14, 2012 at 11:00 AM ET/17:00 CET at the Waldorf Astoria Hotel. A
live audio webcast will be available through the Agennix Web site at
www.agennix.com. A replay will be available on the Web site following
the live event.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company's most advanced program is talactoferrin, an oral
immunotherapy that has demonstrated activity in randomized,
double-blind, placebo-controlled Phase II studies in non-small cell
lung cancer and in severe sepsis. Talactoferrin is currently in Phase
III clinical trials in non-small cell lung cancer and in a Phase
II/III trial in severe sepsis. Other clinical development programs
include RGB-286638, a multi-targeted kinase inhibitor in Phase I
testing for cancer, and a topical gel form of talactoferrin for
diabetic foot ulcers. Agennix's registered seat is in Heidelberg,
Germany. The Company has three sites of operation: Planegg/Munich,
Germany; Princeton, New Jersey and Houston, Texas. For additional
information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. The achievement of
positive results in early stage clinical studies does not ensure that
later stage or large scale clinical studies will be successful. Even
if the results from our later stage trials with talactoferrin,
including the ongoing FORTIS-M trial in non-small cell lung cancer,
are considered positive, there can be no guarantee that they will be
sufficient to gain marketing approval in the United States or any
other country, and regulatory authorities may require additional
information, data and/or further pre-clinical or clinical studies to
support approval. In such event, there can be no guarantee that the
Company will have or be able to obtain the financial resources to
conduct any such additional studies or that such studies will yield
results sufficient for approval. Forward-looking statements speak
only as of the date on which they are made and Agennix undertakes no
obligation to update these forward-looking statements, even if new
information becomes available in the future.

Agennix(TM) is a trademark of the Agennix group.

Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In den USA: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Senior Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: ir@agennix.com
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
regulated dealing/prime standard: Frankfurt
language: English